Sawicki Mark W 4
4 · Cryoport, Inc. · Filed Mar 19, 2024
Insider Transaction Report
Form 4
Cryoport, Inc.CYRX
Sawicki Mark W
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
[F1]2024-03-09+2,666→ 75,791 total - Sale
Common Stock
[F2]2024-03-11$16.35/sh−1,418$23,188→ 74,373 total - Sale
Common Stock
[F2]2024-03-15$15.43/sh−1,312$20,247→ 73,061 total - Award
Common Stock
[F3]2024-03-15+5,750→ 78,811 total - Exercise/Conversion
Restricted Stock Rights
[F4][F1]2024-03-09−2,666→ 2,667 total→ Common Stock (2,666 underlying) - Award
Stock Option (right to buy)
[F5]2024-03-15+11,500→ 11,500 totalExercise: $16.70Exp: 2031-03-15→ Common Stock (11,500 underlying)
Footnotes (5)
- [F1]Represents the conversion of restricted stock rights to shares of common stock upon vesting. Each restricted stock right represents a contingent right to receive one share of CYRX common stock.
- [F2]Shares required to be sold in accordance with the Issuer's policies, in payment of taxes due upon the vesting of restricted stock rights.
- [F3]Represents restricted stock rights, which are a contingent right to receive one share of CYRX common stock, that vest in four equal annual installments beginning March 15, 2025.
- [F4]The originally granted restricted stock rights vest in four equal annual installments beginning March 9, 2022, and have no expiration date. The restricted stock rights reported herein vested and converted to shares of CYRX common stock on a one-for-one basis on March 9, 2024.
- [F5]1/48 of options vest on the 15th of each month for forty-eight months beginning April 25, 2024.
Signature
/s/ Mark Sawicki|2024-03-19